B+
Bull case
25%
Probability
Target price
$118.00
+41.8% vs current
MDT
MedtronicCNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$103.00
+23.8% vs current
B-
Bear case
25%
Probability
Target price
$72.00
-13.5% vs current
AI sentiment snapshot
Latest data as of 2026-06-06
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+64.6
Score
AI commentary
Primary-source tone is constructive and the stock reacted positively on June 3-4, but this remains a T+3 follow-up with limited analyst-revision coverage; social, options, short-interest, and employee-sentiment context were not available in the packet, so confidence is moderate rather than high.
RankAlpha Sentiment Codex - 2026-06-06
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-06-06catalystPost-earnings follow-through after FY26 beatMedium impact
The June 3 release showed Q4 revenue of $9.8B (+9.9% reported, +6.6% organic) and non-GAAP EPS of $1.55 ahead of guidance, while FY26 revenue grew 8.4% reported and 5.8% organic; management also called out the strongest annual top-line growth in 10 years [#SEC-8K-2026-06-03].
2026-06-20eventAnalyst revision follow-through remains thinMedium impact
Before the print, the packet showed a 0.4% cut to consensus EPS over the prior 30 days and a Sell-ranked Zacks view; if post-print estimate and target upgrades stay sparse, some of the earnings-day rally could fade [#PR-EARNINGS-2026-05-29].
2027-04-30catalystPipeline and launch conversion can extend FY27 growthMedium impact
Cardiac Ablation Solutions grew 78% globally, including 124% U.S. growth; Medtronic also filed the U.S. FDA submission for Hugo RAS general surgery and gynecologic indications and reported FDA/CE milestones for Stealth AXiS, supporting a launch-conversion watchlist for FY27 [#SEC-8K-2026-06-03].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-06 • Updated nightlySource: Internal modelMethodology